Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Orthodontic burden of care for patients with a cleft lip and/or palate.

Hameed O, Amin N, Haria P, Patel B, Hay N.

J Orthod. 2019 Mar;46(1):63-67. doi: 10.1177/1465312518823010. Epub 2019 Jan 23.

PMID:
31056071
2.

Fuelling cancer cells.

Terry AR, Hay N.

Nat Rev Endocrinol. 2019 Feb;15(2):71-72. doi: 10.1038/s41574-018-0146-6. Review. No abstract available.

3.

Hepatic HKDC1 Expression Contributes to Liver Metabolism.

Pusec CM, De Jesus A, Khan MW, Terry AR, Ludvik AE, Xu K, Giancola N, Pervaiz H, Daviau Smith E, Ding X, Harrison S, Chandel NS, Becker TC, Hay N, Ardehali H, Cordoba-Chacon J, Layden BT.

Endocrinology. 2019 Feb 1;160(2):313-330. doi: 10.1210/en.2018-00887.

PMID:
30517626
4.

Lysophosphatidic acid and its receptor LPA1 mediate carrageenan induced inflammatory pain in mice.

Srikanth M, Chew WS, Hind T, Lim SM, Hay NWJ, Lee JHM, Rivera R, Chun J, Ong WY, Herr DR.

Eur J Pharmacol. 2018 Dec 15;841:49-56. doi: 10.1016/j.ejphar.2018.10.005. Epub 2018 Oct 12.

PMID:
30321532
5.

Quantitative Lipid Imaging Reveals a New Signaling Function of Phosphatidylinositol-3,4-Bisphophate: Isoform- and Site-Specific Activation of Akt.

Liu SL, Wang ZG, Hu Y, Xin Y, Singaram I, Gorai S, Zhou X, Shim Y, Min JH, Gong LW, Hay N, Zhang J, Cho W.

Mol Cell. 2018 Sep 20;71(6):1092-1104.e5. doi: 10.1016/j.molcel.2018.07.035. Epub 2018 Aug 30.

PMID:
30174291
6.

Hexokinase 2 is dispensable for T cell-dependent immunity.

Mehta MM, Weinberg SE, Steinert EM, Chhiba K, Martinez CA, Gao P, Perlman HR, Bryce P, Hay N, Chandel NS.

Cancer Metab. 2018 Aug 17;6:10. doi: 10.1186/s40170-018-0184-5. eCollection 2018.

7.

Hexokinase 2 as a novel selective metabolic target for rheumatoid arthritis.

Bustamante MF, Oliveira PG, Garcia-Carbonell R, Croft AP, Smith JM, Serrano RL, Sanchez-Lopez E, Liu X, Kisseleva T, Hay N, Buckley CD, Firestein GS, Murphy AN, Miyamoto S, Guma M.

Ann Rheum Dis. 2018 Nov;77(11):1636-1643. doi: 10.1136/annrheumdis-2018-213103. Epub 2018 Jul 30.

PMID:
30061164
8.

Author Correction: Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.

DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR, Hay N.

Nat Commun. 2018 Jun 26;9(1):2539. doi: 10.1038/s41467-018-04182-z.

9.

Aerobic Glycolysis Is Essential for Normal Rod Function and Controls Secondary Cone Death in Retinitis Pigmentosa.

Petit L, Ma S, Cipi J, Cheng SY, Zieger M, Hay N, Punzo C.

Cell Rep. 2018 May 29;23(9):2629-2642. doi: 10.1016/j.celrep.2018.04.111.

10.

Selective eradication of cancer displaying hyperactive Akt by exploiting the metabolic consequences of Akt activation.

Nogueira V, Patra KC, Hay N.

Elife. 2018 Apr 24;7. pii: e32213. doi: 10.7554/eLife.32213.

11.

Expanding the concepts of cancer metabolism.

Jeon SM, Hay N.

Exp Mol Med. 2018 Apr 16;50(4):32. doi: 10.1038/s12276-018-0070-9. No abstract available.

12.
13.

Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.

DeWaal D, Nogueira V, Terry AR, Patra KC, Jeon SM, Guzman G, Au J, Long CP, Antoniewicz MR, Hay N.

Nat Commun. 2018 Jan 31;9(1):446. doi: 10.1038/s41467-017-02733-4. Erratum in: Nat Commun. 2018 Jun 26;9(1):2539.

14.

Hexokinase II may be dispensable for CD4 T cell responses against a virus infection.

Varanasi SK, Jaggi U, Hay N, Rouse BT.

PLoS One. 2018 Jan 19;13(1):e0191533. doi: 10.1371/journal.pone.0191533. eCollection 2018.

15.

Akt2 (Protein Kinase B Beta) Stabilizes ATP7A, a Copper Transporter for Extracellular Superoxide Dismutase, in Vascular Smooth Muscle: Novel Mechanism to Limit Endothelial Dysfunction in Type 2 Diabetes Mellitus.

Sudhahar V, Okur MN, Bagi Z, O'Bryan JP, Hay N, Makino A, Patel VS, Phillips SA, Stepp D, Ushio-Fukai M, Fukai T.

Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):529-541. doi: 10.1161/ATVBAHA.117.309819. Epub 2018 Jan 4.

16.

Fourteen polymorphic microsatellite markers for a widespread limestone endemic, Carex eburnea (Cyperaceae: Carex sect. Albae).

Gillespie EL, Pauley AG, Haffner ML, Hay NM, Estep MC, Murrell ZE.

Appl Plant Sci. 2017 Aug 21;5(8). pii: apps.1700031. doi: 10.3732/apps.1700031. eCollection 2017 Aug.

17.

Prenatal ultrasound detection of micrognathia and its association with Robin sequence.

Kimakhe J, Gilleard O, Swan MC, Pandya P, Thakur V, Ushakov F, Regan L, Minhas M, Bailey J, Hughes J, Codling P, Morris P, Thorburn G, Lees M, McEvoy M, Abel F, Cochrane L, Harding L, Nambiar S, Chorbachi R, Seselgyte R, Hay N, Patel B, Kangesu L.

J Plast Reconstr Aesthet Surg. 2017 Sep;70(9):1308-1311. doi: 10.1016/j.bjps.2017.06.043. Epub 2017 Jul 8. No abstract available.

PMID:
28734755
18.

A Case of Pulmonary Mucormycosis in a Renal Transplant Recipient.

Turnbull A, Chembo CL, Leikis M, Pidgeon G, Arnold L, Hay N, Matheson P.

Nephrology (Carlton). 2017 Aug;22(8):657. doi: 10.1111/nep.12855. No abstract available.

PMID:
28685939
19.

Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).

Wang Q, Chen X, Hay N.

Br J Cancer. 2017 Jul 11;117(2):159-163. doi: 10.1038/bjc.2017.153. Epub 2017 May 30. Review.

20.

FGF-dependent metabolic control of vascular development.

Yu P, Wilhelm K, Dubrac A, Tung JK, Alves TC, Fang JS, Xie Y, Zhu J, Chen Z, De Smet F, Zhang J, Jin SW, Sun L, Sun H, Kibbey RG, Hirschi KK, Hay N, Carmeliet P, Chittenden TW, Eichmann A, Potente M, Simons M.

Nature. 2017 May 11;545(7653):224-228. doi: 10.1038/nature22322. Epub 2017 May 3.

21.

Forkhead box protein 3 (FoxP3) mRNA as a diagnostic marker in ovarian tumors: a pilot study.

Abdel-Hay NH, Mansour AA, El Sherbini MA, Motaleb FIA, El-Shalakany AH.

Eur J Gynaecol Oncol. 2017;38(2):251-256.

PMID:
29953790
22.

Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy?

Hay N.

Nat Rev Cancer. 2016 Oct;16(10):635-49. doi: 10.1038/nrc.2016.77. Epub 2016 Sep 16. Review.

23.

Akt1 promotes stimuli-induced endothelial-barrier protection through FoxO-mediated tight-junction protein turnover.

Gao F, Artham S, Sabbineni H, Al-Azayzih A, Peng XD, Hay N, Adams RH, Byzova TV, Somanath PR.

Cell Mol Life Sci. 2016 Oct;73(20):3917-33. doi: 10.1007/s00018-016-2232-z. Epub 2016 Apr 25.

24.

Spontaneous Hepatocellular Carcinoma after the Combined Deletion of Akt Isoforms.

Wang Q, Yu WN, Chen X, Peng XD, Jeon SM, Birnbaum MJ, Guzman G, Hay N.

Cancer Cell. 2016 Apr 11;29(4):523-535. doi: 10.1016/j.ccell.2016.02.008. Epub 2016 Mar 17.

25.

Stability and function of adult vasculature is sustained by Akt/Jagged1 signalling axis in endothelium.

Kerr BA, West XZ, Kim YW, Zhao Y, Tischenko M, Cull RM, Phares TW, Peng XD, Bernier-Latmani J, Petrova TV, Adams RH, Hay N, Naga Prasad SV, Byzova TV.

Nat Commun. 2016 Mar 14;7:10960. doi: 10.1038/ncomms10960.

26.

NICE guidance on panobinostat for patients with multiple myeloma after at least two previous treatments.

Hall CJ, Doss S, Hay N, Sutcliffe F, Stevens A.

Lancet Oncol. 2016 Mar;17(3):279-80. doi: 10.1016/S1470-2045(16)00061-9. Epub 2016 Jan 27. No abstract available.

PMID:
26827243
27.

Community pharmacist intervention in patients with renal impairment.

Pourrat X, Sipert AS, Gatault P, Sautenet B, Hay N, Guinard F, Guegan F, Halimi JM.

Int J Clin Pharm. 2015 Dec;37(6):1172-9. doi: 10.1007/s11096-015-0182-4. Epub 2015 Sep 18.

PMID:
26385098
28.

NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer.

Hall CJ, Hay N, George E, Adler AI.

Lancet Oncol. 2015 Sep;16(9):1019-1020. doi: 10.1016/S1470-2045(15)00189-8. Epub 2015 Jul 22. No abstract available.

PMID:
26209505
29.

Sixteen polymorphic microsatellite markers for a federally threatened species, Hexastylis naniflora (Aristolochiaceae), and co-occurring congeners.

Hamstead JW, Snider BL, Oaks R, Fitzgerald E, Woodward J, Teat A, Hay NM, Estep MC, Murrell ZE.

Appl Plant Sci. 2015 Jul 7;3(7). pii: apps.1500033. doi: 10.3732/apps.1500033. eCollection 2015 Jul.

30.

Systemic Akt1 Deletion after Tumor Onset in p53(-/-) Mice Increases Lifespan and Regresses Thymic Lymphoma Emulating p53 Restoration.

Yu WN, Nogueira V, Sobhakumari A, Patra KC, Bhaskar PT, Hay N.

Cell Rep. 2015 Jul 28;12(4):610-21. doi: 10.1016/j.celrep.2015.06.057. Epub 2015 Jul 16.

31.

A Reliable Method to Measure Lip Height Using Photogrammetry in Unilateral Cleft Lip Patients.

van der Zeeuw F, Murabit A, Volcano J, Torensma B, Patel B, Hay N, Thorburn G, Morris P, Sommerlad B, Gnarra M, van der Horst C, Kangesu L.

J Craniofac Surg. 2015 Sep;26(6):1865-70. doi: 10.1097/SCS.0000000000001931.

PMID:
26147027
32.

Impact of orthodontic appliances on the quality of craniofacial anatomical magnetic resonance imaging and real-time speech imaging.

Wylezinska M, Pinkstone M, Hay N, Scott AD, Birch MJ, Miquel ME.

Eur J Orthod. 2015 Dec;37(6):610-7. doi: 10.1093/ejo/cju103. Epub 2015 Feb 8.

PMID:
25667040
33.

The double-edged sword of AMPK signaling in cancer and its therapeutic implications.

Jeon SM, Hay N.

Arch Pharm Res. 2015 Mar;38(3):346-57. doi: 10.1007/s12272-015-0549-z. Epub 2015 Jan 10. Review.

34.

Evidence for heightened hexokinase II immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma.

Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie H, Hay N.

Dig Dis Sci. 2015 Feb;60(2):420-6. doi: 10.1007/s10620-014-3364-3. Epub 2014 Nov 8.

35.

The pentose phosphate pathway and cancer.

Patra KC, Hay N.

Trends Biochem Sci. 2014 Aug;39(8):347-54. doi: 10.1016/j.tibs.2014.06.005. Epub 2014 Jul 15. Review.

36.

A case report of a rare finding of supernumerary primary and permanent canines.

Parker K, Hay N.

J Int Oral Health. 2014 Apr;6(2):129-31. Epub 2014 Apr 26.

37.

NICE guidance on pixantrone monotherapy for multiply relapsed or refractory aggressive non-Hodgkin lymphoma.

Landells LJ, Prescott C, Hay N, Sutcliffe F, Stevens A.

Lancet Oncol. 2014 Apr;15(4):381-2. No abstract available.

PMID:
24818252
38.

Neutrophil AKT2 regulates heterotypic cell-cell interactions during vascular inflammation.

Li J, Kim K, Hahm E, Molokie R, Hay N, Gordeuk VR, Du X, Cho J.

J Clin Invest. 2014 Apr;124(4):1483-96. doi: 10.1172/JCI72305. Epub 2014 Mar 18.

39.

Hexokinase 2 as oncotarget.

Patra KC, Hay N.

Oncotarget. 2013 Nov;4(11):1862-3. No abstract available.

40.

Prolonged vitamin D intoxication: presentation, pathogenesis and progress.

Bell DA, Crooke MJ, Hay N, Glendenning P.

Intern Med J. 2013 Oct;43(10):1148-50. doi: 10.1111/imj.12269.

PMID:
24134173
41.

Extracellular heat shock protein 90 signals through subdomain II and the NPVY motif of LRP-1 receptor to Akt1 and Akt2: a circuit essential for promoting skin cell migration in vitro and wound healing in vivo.

Tsen F, Bhatia A, O'Brien K, Cheng CF, Chen M, Hay N, Stiles B, Woodley DT, Li W.

Mol Cell Biol. 2013 Dec;33(24):4947-59. doi: 10.1128/MCB.00559-13. Epub 2013 Oct 14.

42.

Common dental features and craniofacial development of three siblings with Ter Haar syndrome.

Parker K, Pabla R, Hay N, Ayliffe P.

Eur Arch Paediatr Dent. 2014 Feb;15(1):59-64. doi: 10.1007/s40368-013-0092-x. Epub 2013 Oct 2.

PMID:
24085649
43.

MADD is a downstream target of PTEN in triggering apoptosis.

Jayarama S, Li LC, Ganesh L, Mardi D, Kanteti P, Hay N, Li P, Prabhakar BS.

J Cell Biochem. 2014 Feb;115(2):261-70. doi: 10.1002/jcb.24657.

44.

Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer.

Patra KC, Wang Q, Bhaskar PT, Miller L, Wang Z, Wheaton W, Chandel N, Laakso M, Muller WJ, Allen EL, Jha AK, Smolen GA, Clasquin MF, Robey B, Hay N.

Cancer Cell. 2013 Aug 12;24(2):213-228. doi: 10.1016/j.ccr.2013.06.014. Epub 2013 Aug 1. Erratum in: Cancer Cell. 2013 Sep 9;24(3):399.

45.

PTK6 activation at the membrane regulates epithelial-mesenchymal transition in prostate cancer.

Zheng Y, Wang Z, Bie W, Brauer PM, Perez White BE, Li J, Nogueira V, Raychaudhuri P, Hay N, Tonetti DA, Macias V, Kajdacsy-Balla A, Tyner AL.

Cancer Res. 2013 Sep 1;73(17):5426-37. doi: 10.1158/0008-5472.CAN-13-0443. Epub 2013 Jul 15. Erratum in: Cancer Res. 2013 Oct 1;73(19):6096.

46.

ROS inhibitor N-acetyl-L-cysteine antagonizes the activity of proteasome inhibitors.

Halasi M, Wang M, Chavan TS, Gaponenko V, Hay N, Gartel AL.

Biochem J. 2013 Sep 1;454(2):201-8. doi: 10.1042/BJ20130282.

47.

Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy.

Nogueira V, Hay N.

Clin Cancer Res. 2013 Aug 15;19(16):4309-14. doi: 10.1158/1078-0432.CCR-12-1424. Epub 2013 May 29. Review.

48.

Communication between community and hospital pharmacists: impact on medication reconciliation at admission.

Pourrat X, Corneau H, Floch S, Kuzzay MP, Favard L, Rosset P, Hay N, Grassin J.

Int J Clin Pharm. 2013 Aug;35(4):656-63. doi: 10.1007/s11096-013-9788-6. Epub 2013 May 18.

PMID:
23686408
49.

The dark face of AMPK as an essential tumor promoter.

Jeon SM, Hay N.

Cell Logist. 2012 Oct 1;2(4):197-202.

50.

Combination of oxidative stress and FOXM1 inhibitors induces apoptosis in cancer cells and inhibits xenograft tumor growth.

Halasi M, Pandit B, Wang M, Nogueira V, Hay N, Gartel AL.

Am J Pathol. 2013 Jul;183(1):257-65. doi: 10.1016/j.ajpath.2013.03.012. Epub 2013 May 10.

Supplemental Content

Support Center